Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Left ventricle

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    147 result(s) found for: Left ventricle. Displaying page 8 of 8.
    « Previous 1  2  3  4  5  6  7  8 
    EudraCT Number: 2013-001358-81 Sponsor Protocol Number: CTPX01 Start Date*: 2014-05-20
    Sponsor Name:Coretherapix S.L.U.
    Full Title: "First-in-human clinical trial, double blind, randomized with placebo, open for the six first patients (dose ranging), to evaluate the safety and efficacy of intracoronary infusion of allogeneic hu...
    Medical condition: Acute Myocardial Infarction (AMI): "First STEMI submitted to elective primary PCI with successful revascularization by PCI (TIMI = 3), but intermediate-high risk of HF development (infarct size by...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002016-26 Sponsor Protocol Number: FBCSG-01-2007 Start Date*: 2007-08-08
    Sponsor Name:Finnish Breast Cancer Group
    Full Title: A randomized phase III study comparing trastuzumab plus docetaxel (HT) followed by 5-FU, epirubicin, and cyclophosphamide (FEC) to the same regimen followed by single-agent trastuzumab as adjuvant ...
    Medical condition: Invasive early breast cancer that has been removed by surgery.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: FI (Completed) SE (Completed) GB (GB - no longer in EU/EEA) IS (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003284-35 Sponsor Protocol Number: ABX464-102 Start Date*: 2017-12-19
    Sponsor Name:ABIVAX
    Full Title: A follow-up Phase IIa study to evaluate the long-term safety and efficacy profile of ABX464 given at 50 mg once daily in subjects with Moderate to Severe Active Ulcerative Colitis.
    Medical condition: Moderate to severe Ulcerative Colitis.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10066678 Acute ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) PL (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-000733-39 Sponsor Protocol Number: ABX464-104 Start Date*: 2019-11-21
    Sponsor Name:ABIVAX
    Full Title: A phase 2b, open-label, efficacy and safety study of ABX464 as maintenance therapy in patients with moderate to severe Ulcerative Colitis.
    Medical condition: Moderate to Severe Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10066678 Acute ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) PL (Completed) AT (Completed) SI (Completed) BE (Completed) CZ (Completed) ES (Ongoing) HU (Completed) GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002669-37 Sponsor Protocol Number: GB002-2101 Start Date*: 2020-10-08
    Sponsor Name:GB002, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arter...
    Medical condition: Pulmonary Arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077739 Pulmonary arterial hypertension WHO functional class I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) AT (Completed) CZ (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004073-14 Sponsor Protocol Number: 1245-0168 Start Date*: 2018-04-03
    Sponsor Name:Boehringer-Ingelheim España, S.A.
    Full Title: A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In pa...
    Medical condition: Chronic Heart Failure with reduced Ejection Fraction (HFrEF)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GR (Completed) PT (Completed) PL (Completed) SE (Completed) NO (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-011169-98 Sponsor Protocol Number: GS-US-300-0128 Start Date*: 2009-11-03
    Sponsor Name:Gilead Sciences, Inc
    Full Title: ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibr...
    Medical condition: Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10021240 Idiopathic pulmonary fibrosis LLT
    12.0 10037400 Pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Feb 11 15:52:43 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA